George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMarlowe Regulatory News (MRL)

Share Price Information for Marlowe (MRL)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 498.00
Bid: 496.00
Ask: 500.00
Change: -15.00 (-2.97%)
Spread: 4.00 (0.806%)
Open: 506.00
High: 506.00
Low: 490.00
Prev. Close: 505.00
MRL Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Board Changes; Update re: Returns of Capital

18 Mar 2024 07:00

RNS Number : 1415H
Marlowe PLC
18 March 2024
 

18 March 2024

 

Marlowe plc

("Marlowe" or the "Company")

 

Board Changes; Update re: Returns of Capital

 

Further to the announcement of 22 February 2024 on the sale of certain Governance, Risk & Compliance ("GRC") software and services assets (the "Divestment") for an Enterprise Value of £430m, Marlowe plc ("Marlowe" or the "Group") announces the following changes to its Board:

 

· The appointment of Lord Ashcroft KCMG PC as a Non-Executive Director.

 

· Charles Skinner is today stepping down from the Marlowe Board, having been in role since the company's formation and through to its growth into the UK leader in business-critical services and software. Charles will be replaced by a new Independent Non-Executive Director in due course.

 

 

Update re: Returns of Capital on completion of the Divestment

 

The Group also provides an update on the planned process to return capital to shareholders following completion of the Divestment.

 

Subject to completion, proposed returns of capital would be expected to commence during the first half of the Group's FY25 financial year, beginning 1 April 2024.

 

? After relevant adjustments including estimated transaction costs, settlement of certain transaction-related liabilities and earn-outs, reorganisation and separation costs, the Group expects net Divestment sale proceeds to be c.£405 million.

 

? On completion of the Divestment and the retirement in full of the Group's existing debt facilities, the Group expects its net cash position to be approximately £220 million.

 

? The Group is minded to retain a net cash balance to provide resources for working capital and selected investments and to return in excess of £150 million of remaining net cash to shareholders.

 

? The Board is assessing the optimal route through which to effect the return of capital and will confirm the return in due course.

 

Kevin Quinn, Non-Executive Chairman of Marlowe, commented:

 

"The Board wishes to wholeheartedly thank Charles for his service and commitment to Marlowe. He has served on the Board from the earliest days of Marlowe and has made an outstanding contribution throughout his tenure. He goes with our best wishes for the future.

 

We welcome Lord Ashcroft to the Board of Marlowe."

 

The directorships and partnerships currently held by Michael Anthony Ashcroft, aged 78, and over the five years preceding the date of his appointment, are as follows:

 

Current directorships / partnerships

Previous directorships / partnerships

Impellam Group plc

Imperial War Museum

Merit Group plc

Imperial War Museum Foundation

Waterloo Investment Holdings Limited

Rendeavour Holdings Limited

Heather Global plc

Crimestoppers Trust

Prospect Education (Technology) Trust Limited

 

Lord Ashcroft currently holds 11,877,361 Ordinary Shares in Marlowe, representing 12.3% of the Company's issued share capital.

 

For further information:

 

Marlowe plc

Alex Dacre, Chief Executive

www.marloweplc.com

Adam Councell, Chief Financial Officer

Tel: +44 (0) 203 813 8498

Benjamin Tucker, Head of Investor Relations

Cavendish Capital Markets (Nominated Adviser and Joint Broker)

Ben Jeynes

Tel: +44 (0)20 7220 0500

George Lawson

Berenberg (Joint Broker)

Dan Gee-Summons

Tel: +44 (0)20 3207 7800

Mark Whitmore

Stifel (Joint Broker)

Matthew Blawat

Tel: +44 (0)20 7710 7688

Francis North

FTI Consulting

Nick Hasell

Tel: +44 (0)20 3727 1340

Alex Le May

 

 

About Marlowe plc

 

Marlowe is a UK leader in business-critical services and software which assure regulatory compliance. The company was formed to create sustainable shareholder value through the acquisition and development of businesses that provide regulated safety and compliance services and software. It is focused on compliance software, eLearning, health & safety, employment law & HR compliance, fire safety & security, water & air hygiene and occupational health services - all of which are vital to the wellbeing of its customers operations and are invariably governed by regulation. Marlowe currently provides software to over 1 million users and services to over 25% of Britain's commercial premises. The Group provides customers with a single outsourced, nationwide, provider of a range of regulated compliance and safety solutions. Our customers can be found in office complexes, high streets & leisure facilities, manufacturing plants and industrial estates, and include thousands of SMEs, local authorities, facilities management providers, multi-site NHS trusts and FTSE 100 companies.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOAQDLFFZXLLBBD
Date   Source Headline
8th Apr 20242:54 pmRNSHolding(s) in Company
28th Mar 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
26th Mar 20244:45 pmRNSBlock listing Interim Review
18th Mar 20247:00 amRNSBoard Changes; Update re: Returns of Capital
26th Feb 20247:00 amRNSDirector/PDMR Shareholding and Total Voting Rights
22nd Feb 20247:00 amRNSDisposal and Directorate Change
15th Jan 202410:23 amRNSChange of Nominated Adviser and Joint Broker
30th Nov 20237:00 amRNSTotal Voting Rights
28th Nov 20237:00 amRNSInterim results for the six months to 30 Sept 2023
23rd Nov 20237:00 amRNSNotice of Interim Results
31st Oct 20234:30 pmRNSTotal Voting Rights
27th Sep 20235:18 pmRNSHolding(s) in Company
26th Sep 20233:23 pmRNSBlock Admission
13th Sep 20236:15 pmRNSResult of AGM
13th Sep 20237:00 amRNSAnnual General Meeting and Trading Update
4th Sep 20237:00 amRNSHolding(s) in Company
8th Aug 20237:00 amRNSExercise of Share Options and Total Voting Rights
7th Aug 20237:45 amRNSResponse to Speculation
4th Aug 20233:50 pmRNSHolding(s) in Company
3rd Aug 20235:25 pmRNSHolding(s) in Company
31st Jul 20233:30 pmRNSIssue of Equity and Total Voting Rights
26th Jul 20237:00 amRNSAcquisition of IMSM
18th Jul 202312:15 pmRNSCapital Reduction Effective
13th Jul 20232:00 pmRNSPublication of Notice of AGM and Annual Report
29th Jun 20237:00 amRNSPreliminary results
26th Jun 20237:00 amRNSNotice of Full Year Results
23rd Jun 20234:56 pmRNSHolding(s) in Company
19th Jun 202311:06 amRNSResult of General Meeting
5th Jun 20239:31 amRNSHolding(s) in Company
2nd Jun 20232:51 pmRNSPosting of Circular and Notice of General Meeting
2nd Jun 202312:36 pmRNSHolding(s) in Company
18th Apr 20231:45 pmRNSHolding(s) in Company
29th Mar 20237:00 amRNSCapital Markets Day Replay
28th Mar 20237:00 amRNSCapital Markets Day and Trading Update
7th Mar 20237:00 amRNSNotice of Capital Markets Event
28th Feb 20232:20 pmRNSHolding(s) in Company
26th Jan 20231:46 pmRNSHolding(s) in Company
5th Jan 20237:00 amRNSNotice of Capital Markets Event
2nd Dec 20229:00 amRNSNotice of Investor Presentation
1st Dec 202210:34 amRNSDirector/PDMR Shareholding
1st Dec 20229:00 amRNSDirector/PDMR Shareholding
24th Nov 20222:14 pmRNSDirector/PDMR Shareholding
24th Nov 20221:48 pmRNSDirector/PDMR Shareholding
23rd Nov 20227:00 amRNSHalf-year Report
21st Nov 202212:54 pmRNSExercise of Share Options and Total Voting Rights
17th Nov 20227:00 amRNSNotice of Interim Results
2nd Nov 20225:08 pmRNSHolding(s) in Company
19th Oct 202210:40 amRNSExercise of Share Options and Total Voting Rights
14th Oct 20223:12 pmRNSHolding(s) in Company
11th Oct 20221:40 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.